Literature DB >> 3695478

Pathophysiology of estrogen receptors in mammary tissue by monoclonal antibodies.

G Fabris1, E Marchetti, A Marzola, A Bagni, P Querzoli, I Nenci.   

Abstract

Identification of preneoplastic lesions of the breast has mainly rested on morphological grounds, supported by epidemiological data. These studies assign a definite precancerous potential to a group of atypical hyperplastic lesions and in situ carcinoma. In spite of much effort no criteria are yet available to understand which, among these lesions, is committed to infiltrative growth, in other words, to understand the risk to a single patient. Estrogens are know to play a critical role in the etiology of breast cancer. The hypothesis is investigated that this role is dependent on a modified expression of their receptor. To approach this question estrogen receptor expression was traced by specific monoclonal anti-receptor antibodies and immunocytochemistry, on a spectrum of breast tissue changes, from normal tissue to infiltrating cancer. Estrogen receptor expression is heterogeneous in normal tissue and in infiltrating cancer, and on the contrary is homogeneous in proliferative atypical lesions and in in situ carcinomas. Present results show that receptor expression is enhanced and becomes homogeneous, maybe constitutive, in atypical hyperplasia and in in situ carcinoma and that this phenomenon could subserve important changes of proliferative capacity which are necessary and possibly sufficient for autonomous growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3695478     DOI: 10.1016/0022-4731(87)90307-4

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  7 in total

1.  Ductal Carcinoma In Situ of the Breast: Is Breast Conserving Treatment Feasible?

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Regulation of estrogen receptor α N-terminus conformation and function by peptidyl prolyl isomerase Pin1.

Authors:  Prashant Rajbhandari; Greg Finn; Natalia M Solodin; Kiran K Singarapu; Sarata C Sahu; John L Markley; Kelley J Kadunc; Stephanie J Ellison-Zelski; Anastasia Kariagina; Sandra Z Haslam; Kun Ping Lu; Elaine T Alarid
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

4.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

Review 5.  Amping up estrogen receptors in breast cancer.

Authors:  Amy M Fowler; Elaine T Alarid
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

6.  Aptamer-Assisted Detection of the Altered Expression of Estrogen Receptor Alpha in Human Breast Cancer.

Authors:  Rajesh Ahirwar; Shamsudheen Karuthedath Vellarikkal; Arghya Sett; Sridhar Sivasubbu; Vinod Scaria; Utpal Bora; Bibhuti Bhusan Borthakur; Amal Chandra Kataki; Jagannath Dev Sharma; Pradip Nahar
Journal:  PLoS One       Date:  2016-04-04       Impact factor: 3.240

7.  High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer.

Authors:  T Yamakawa; T Morimoto; M Sasa; S Numoto; Y Monden
Journal:  Jpn J Cancer Res       Date:  1995-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.